161 related articles for article (PubMed ID: 24442606)
21. Benefit of additional screening for progressive multifocal leukoencephalopathy in patients with multiple sclerosis taking natalizumab: a decision analysis.
Landy DC; Hecht EM
Clin Neuropharmacol; 2014; 37(2):45-51. PubMed ID: 24614671
[TBL] [Abstract][Full Text] [Related]
22. Tysabri's return draws cautious optimism. Pharmacies, infusion centers must register to participate.
Traynor K
Am J Health Syst Pharm; 2006 Aug; 63(15):1388, 1392. PubMed ID: 16849700
[No Abstract] [Full Text] [Related]
23. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
Soilu-Hänninen M; Päivärinta M; Sonninen P; Parkkola R; Vuorinen T; Erälinna JP
Duodecim; 2013; 129(7):765-70. PubMed ID: 23720945
[TBL] [Abstract][Full Text] [Related]
24. Surgical management of malignant cerebral edema secondary to immune reconstitution inflammatory syndrome from natalizumab-associated progressive multifocal encephalopathy.
Tan LA; Lopes DK
J Clin Neurosci; 2015 Oct; 22(10):1669-71. PubMed ID: 26115897
[TBL] [Abstract][Full Text] [Related]
25. Natalizumab (tysabri)-associated progressive multifocal leukoencephalopathy: insights from perfusion magnetic resonance imaging.
Elster MJ
J Comput Assist Tomogr; 2013; 37(5):694-7. PubMed ID: 24045242
[TBL] [Abstract][Full Text] [Related]
26. Natalizumab: bench to bedside and beyond.
Rudick R; Polman C; Clifford D; Miller D; Steinman L
JAMA Neurol; 2013 Feb; 70(2):172-82. PubMed ID: 23128399
[TBL] [Abstract][Full Text] [Related]
27. Brain Magnetic Susceptibility Changes in Patients with Natalizumab-Associated Progressive Multifocal Leukoencephalopathy.
Hodel J; Outteryck O; Verclytte S; Deramecourt V; Lacour A; Pruvo JP; Vermersch P; Leclerc X
AJNR Am J Neuroradiol; 2015 Dec; 36(12):2296-302. PubMed ID: 26316568
[TBL] [Abstract][Full Text] [Related]
28. JCV-negative natalizumab-associated progressive multifocal leukoencephalopathy: a clinico-radiological diagnosis.
Travasarou M; Marousi S; Papageorgiou E; Karageorgiou CE
Clin Neurol Neurosurg; 2013 Jun; 115(6):827-9. PubMed ID: 22920632
[No Abstract] [Full Text] [Related]
29. Predicting risk of progressive multifocal leukoencephalopathy from natalizumab.
Ropper AH
N Engl J Med; 2012 May; 366(20):1938-9. PubMed ID: 22591300
[No Abstract] [Full Text] [Related]
30. Natalizumab treatment for multiple sclerosis.
Ferreira ML
Arq Neuropsiquiatr; 2014 Dec; 72(12):911-2. PubMed ID: 25517640
[No Abstract] [Full Text] [Related]
31. Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive.
Fragoso YD; Mendes MF; Arruda WO; Becker J; Brooks JB; Carvalho Mde J; Comini-Frota ER; Domingues RB; Ferreira ML; Finkelsztejn A; Gama PD; Gomes S; Gonçalves MV; Kaimen-Maciel DR; Morales Rde R; Muniz A; Ruocco HH; Salgado PR; Albuquerque LB; Gama RA; Georgeto S; Lopes J; Oliveira CL; Oliveira FT; Safanelli J; Saldanha PC; Satomi M
Arq Neuropsiquiatr; 2013 Oct; 71(10):780-2. PubMed ID: 24212514
[TBL] [Abstract][Full Text] [Related]
32. Natalizumab (TYSABRI) and multiple sclerosis. With longer follow-up: even more toxic than suspected.
Prescrire Int; 2015 Mar; 24(158):65-7. PubMed ID: 25897454
[TBL] [Abstract][Full Text] [Related]
33. Fingolimod and multiple sclerosis: four cautionary tales.
Bourdette D; Gilden D
Neurology; 2012 Nov; 79(19):1942-3. PubMed ID: 23035058
[No Abstract] [Full Text] [Related]
34. Drug-induced progressive multifocal leukoencephalopathy: Lessons learned from contrasting natalizumab and rituximab.
Vermeer NS; Straus SM; Mantel-Teeuwisse AK; Hidalgo-Simon A; Egberts AC; Leufkens HG; De Bruin ML
Clin Pharmacol Ther; 2015 Nov; 98(5):542-50. PubMed ID: 26347128
[TBL] [Abstract][Full Text] [Related]
35. Multiple sclerosis woes.
Nat Neurosci; 2005 Jul; 8(7):837. PubMed ID: 16136665
[No Abstract] [Full Text] [Related]
36. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.
Boster AL; Nicholas JA; Topalli I; Kisanuki YY; Pei W; Morgan-Followell B; Kirsch CF; Racke MK; Pitt D
JAMA Neurol; 2013 Mar; 70(3):398-402. PubMed ID: 23338729
[TBL] [Abstract][Full Text] [Related]
37. Use of natalizumab in multiple sclerosis: current perspectives.
Gandhi S; Jakimovski D; Ahmed R; Hojnacki D; Kolb C; Weinstock-Guttman B; Zivadinov R
Expert Opin Biol Ther; 2016 Sep; 16(9):1151-62. PubMed ID: 27413840
[TBL] [Abstract][Full Text] [Related]
38. Value of MRI as a surrogate marker for PML in natalizumab long-term therapy.
Ayzenberg I; Lukas C; Trampe N; Gold R; Hellwig K
J Neurol; 2012 Aug; 259(8):1732-3. PubMed ID: 22289971
[No Abstract] [Full Text] [Related]
39. Natalizumab-associated progressive multifocal leukoencephalopathy.
Mancini N; Clementi M; Burioni R
N Engl J Med; 2012 Aug; 367(9):871-2; author reply 872. PubMed ID: 22931329
[No Abstract] [Full Text] [Related]
40. Natalizumab-associated progressive multifocal leukoencephalopathy.
Cervera C
N Engl J Med; 2012 Aug; 367(9):871; author reply 872. PubMed ID: 22931328
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
